NRG THERAPEUTICS LTD

11294505
Active Stevenage

Research and experimental development on biotechnology

7 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
N

NRG THERAPEUTICS LTD

11294505

Research and experimental development on biotechnology

Founded 5 Apr 2018 Active Stevenage, United Kingdom 7 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
Accounts Submitted 13 Oct 2025 Next due 31 Jan 2027 7 months remaining
Confirmation Submitted 19 Apr 2026 Next due 18 Apr 2027 10 months remaining
Net assets £2M £3M 2025 year on year
Total assets £4M £2M 2025 year on year
Total Liabilities £2M £398K 2025 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

Stevenage Bioscience Catalyst Gunnels Wood Road Stevenage Herts SG1 2FX United Kingdom

Telephone

0800 000 0000

Website

www.example.com

Full company profile for NRG THERAPEUTICS LTD (11294505), an active life sciences and medical technology company based in Stevenage, United Kingdom. Incorporated 5 Apr 2018. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 May → 30 Apr 2025
Type small
Next accounts 30 Apr 2026
Due by 31 Jan 2027 7 months remaining

Net Assets, Total Assets & Total Liabilities (2019–2025)

Cash in Bank

£3.56M

Decreased by £1.69M (-32%)

Net Assets

£2.28M

Decreased by £2.63M (-54%)

Total Liabilities

£2.19M

Increased by £398.00k (+22%)

Turnover

N/A

Employees

7

Increased by 1 (+17%)

Debt Ratio

49%

Increased by 22 (+81%)

Financial History

Revenue, profit, EBITDA and key financial figures

2025
30 Apr Year End
2024
30 Apr Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 2
Grants 1

Investors (4)

Investor NameInvestor SinceParticipating Rounds
Investor 7Nov 2022Series A
Investor 8Nov 2022Series A
Investor 9Nov 2022Series A

Share Capital

Share Capital

Share allotments and capital structure

9 Allotments 10,786,151 Shares £42.12m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
24 Feb 20264,032,257£20.00m£4.96
27 Aug 2025387,097£1.92m£4.96
14 Jul 20252,032,258£10.08m£4.96
14 May 2024100,807£500k£4.96
7 Jul 2022600,000£600£0.001

Officers

Officers

3 active
Status
Emma JohnsonDirectorBritishUnited Kingdom302 Jul 2025Active
Laurence Daniel Paul BarkerDirectorBritishUnited Kingdom542 Jul 2025Active
Nessi, ClaudioDirectorSwissSwitzerland5730 Jun 2022Active

Shareholders

Shareholders (24)

Omega Fund Vii, Lp
25.6%
3,024,194
Omega Fund Vii, Lp
12.9%
1,516,129

Persons with Significant Control

Persons with Significant Control (1)

1 Active 5 Ceased
Notified 7 Jul 2022
Nature of Control
  • Ownership Of Shares 25 To 50 Percent,voting Rights 25 To 50 Percent

Grant Hawthorne

Ceased 30 Jun 2022

Ceased

Neil Derek Miller

Ceased 30 Jun 2022

Ceased
Ceased

Anthony Richard Rutter

Ceased 30 Jun 2022

Ceased

Parkinson's Uk

Ceased 27 Jun 2019

Ceased

Group Structure

Group Structure

NRG THERAPEUTICS LTD Current Company

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
19 Apr 2026Confirmation StatementConfirmation statement made on 4 Apr 2026 with updates
24 Feb 2026CapitalAllotment of shares (GBP 8,162.7627) on 24 Feb 2026
4 Feb 2026OfficersTermination of Laurence Daniel Paul Barker as director on 2 Feb 2026
4 Feb 2026OfficersAppointment of Georgia Rose Frost as director on 2 Feb 2026
12 Dec 2025OfficersTermination of Emma Johnson as director on 10 Dec 2025
19 Apr 2026 Confirmation Statement

Confirmation statement made on 4 Apr 2026 with updates

24 Feb 2026 Capital

Allotment of shares (GBP 8,162.7627) on 24 Feb 2026

4 Feb 2026 Officers

Termination of Laurence Daniel Paul Barker as director on 2 Feb 2026

4 Feb 2026 Officers

Appointment of Georgia Rose Frost as director on 2 Feb 2026

12 Dec 2025 Officers

Termination of Emma Johnson as director on 10 Dec 2025

Recent Activity

Latest Activity

Confirmation statement made on 4 Apr 2026 with updates

1 months ago on 19 Apr 2026

Allotment of shares (GBP 8,162.7627) on 24 Feb 2026

3 months ago on 24 Feb 2026

Termination of Laurence Daniel Paul Barker as director on 2 Feb 2026

4 months ago on 4 Feb 2026

Appointment of Georgia Rose Frost as director on 2 Feb 2026

4 months ago on 4 Feb 2026

Termination of Emma Johnson as director on 10 Dec 2025

6 months ago on 12 Dec 2025